Not available
Quote | Aileron Therapeutics Inc. (NASDAQ:ALRN)
Last: | $2.87 |
---|---|
Change Percent: | 5.28% |
Open: | $2.69 |
Close: | $2.87 |
High: | $3.15 |
Low: | $2.69 |
Volume: | 229,536 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Aileron Therapeutics Inc. (NASDAQ:ALRN)
Aileron Therapeutics to be Included in the Russell Microcap® Index PR Newswire AUSTIN, Texas , July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of...
2024-05-15 17:47:41 ET More on Aileron Therapeutics Aileron announces pricing of underwritten registered direct offering priced at-the-market under Nasdaq rules of up to about $40M Aileron Therapeutics announces positive data from its early stage pulmonary fibrosis treatment...
Message Board Posts | Aileron Therapeutics Inc. (NASDAQ:ALRN)
Subject | By | Source | When |
---|---|---|---|
Ending development - cutting staff and looking for | ErnieBilco | investorshub | 02/21/2023 5:15:35 PM |
whytestocks: $ALRN News Article - Aileron Therapeutics Reports Third Quarter 2022 Financial Results | whytestocks | investorshangout | 11/01/2022 12:25:50 PM |
whytestocks: $ALRN News Article - Aileron Therapeutics to Present and Participate in a Fireside Chat | whytestocks | investorshangout | 09/22/2022 12:10:50 PM |
tommy56: Thanks for this post the author should try to educate us about software engineering researc | tommy56 | investorshangout | 09/15/2022 12:01:43 PM |
znewcar1: ALRN 38% v13,3M c.2702 f90,8M H.316 Haft3.198 | znewcar1 | investorshangout | 09/14/2022 10:10:07 PM |
News, Short Squeeze, Breakout and More Instantly...
Aileron Therapeutics Inc. Company Name:
ALRN Stock Symbol:
NASDAQ Market:
Aileron Therapeutics Inc. Website:
Aileron Therapeutics to be Included in the Russell Microcap® Index PR Newswire AUSTIN, Texas , July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of...
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...